NASDAQ:MBIO - Mustang Bio Stock Price, Forecast & News

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Mustang Bio Inc (NASDAQ:MBIO) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.01. View Mustang Bio's Earnings History.

Mustang Bio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Mustang Bio.

3 brokers have issued 1 year price targets for Mustang Bio's stock. Their forecasts range from $7.00 to $18.00. On average, they anticipate Mustang Bio's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 170.7% from the stock's current price. View Analyst Price Targets for Mustang Bio.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mustang Bio.

Press coverage about MBIO stock has trended somewhat negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mustang Bio earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Mustang Bio.

Mustang Bio saw a increase in short interest in December. As of December 31st, there was short interest totalling 610,700 shares, an increase of 9.1% from the December 15th total of 560,000 shares. Based on an average daily volume of 337,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 2.2% of the company's shares are short sold. View Mustang Bio's Current Options Chain.

Some companies that are related to Mustang Bio include Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Kura Oncology (KURA), MacroGenics (MGNX), Milestone Pharmaceuticals (MIST), Atreca (BCEL), Neoleukin Therapeutics (NLTX), BioDelivery Sciences International (BDSI), Prothena (PRTA), Molecular Templates (MTEM) and Clovis Oncology (CLVS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include Zynerba Pharmaceuticals (ZYNE), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Antares Pharma (ATRS), Cara Therapeutics (CARA), Amicus Therapeutics (FOLD) and Harrow Health (HROW).

Mustang Bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.32%). View Institutional Ownership Trends for Mustang Bio.

MBIO stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Mustang Bio.

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MBIO stock can currently be purchased for approximately $3.94.

Mustang Bio has a market capitalization of $159.82 million. The company earns $-30,660,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Mustang Bio employs 38 workers across the globe.View Additional Information About Mustang Bio.

The official website for Mustang Bio is http://www.mustangbio.com/.

Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]